120 related articles for article (PubMed ID: 9561111)
21. 5-Lipoxygenase-activating protein is the target of a novel hybrid of two classes of leukotriene biosynthesis inhibitors.
Mancini JA; Prasit P; Coppolino MG; Charleson P; Leger S; Evans JF; Gillard JW; Vickers PJ
Mol Pharmacol; 1992 Feb; 41(2):267-72. PubMed ID: 1538707
[TBL] [Abstract][Full Text] [Related]
22. Translocation of HL-60 cell 5-lipoxygenase. Inhibition of A23187- or N-formyl-methionyl-leucyl-phenylalanine-induced translocation by indole and quinoline leukotriene synthesis inhibitors.
Kargman S; Prasit P; Evans JF
J Biol Chem; 1991 Dec; 266(35):23745-52. PubMed ID: 1748650
[TBL] [Abstract][Full Text] [Related]
23. Inhibition by troglitazone of the antigen-induced production of leukotrienes in immunoglobulin E-sensitized RBL-2H3 cells.
Yamashita M; Kushihara M; Hirasawa N; Takasaki W; Takahagi H; Takayanagi M; Ohuchi K
Br J Pharmacol; 2000 Jan; 129(2):367-73. PubMed ID: 10694244
[TBL] [Abstract][Full Text] [Related]
24. L-652,343, a novel dual cyclo/lipoxygenase inhibitor, inhibits LTB4-production by stimulated human polymorphonuclear cells but not by stimulated human whole blood.
Gresele P; Arnout J; Deckmyn H; Vermylen J
Biochem Pharmacol; 1987 Oct; 36(20):3529-31. PubMed ID: 2823826
[No Abstract] [Full Text] [Related]
25. 5-Lipoxygenase-activating protein is the target of a quinoline class of leukotriene synthesis inhibitors.
Evans JF; Lévillé C; Mancini JA; Prasit P; Thérien M; Zamboni R; Gauthier JY; Fortin R; Charleson P; MacIntyre DE
Mol Pharmacol; 1991 Jul; 40(1):22-7. PubMed ID: 1857337
[TBL] [Abstract][Full Text] [Related]
26. Inversely-correlated inhibition of human 5-lipoxygenase activity by BAY X1005 and other quinoline derivatives in intact cells and a cell-free system--implications for the function of 5-lipoxygenase activating protein.
Hatzelmann A; Goossens J; Fruchtmann R; Mohrs KH; Raddatz S; Müller-Peddinghaus R
Biochem Pharmacol; 1994 Jun; 47(12):2259-68. PubMed ID: 8031320
[TBL] [Abstract][Full Text] [Related]
27. Selective effects of antileukotrienes on leukotriene and histamine release in human dispersed lung cells.
Larsson L; Sydbom A; Dahlén SE
Inflamm Res; 1999 Apr; 48 Suppl 1():S9-10. PubMed ID: 10350138
[No Abstract] [Full Text] [Related]
28. Symmetrical bis(heteroarylmethoxyphenyl)alkylcarboxylic acids as inhibitors of leukotriene biosynthesis.
Kolasa T; Gunn DE; Bhatia P; Basha A; Craig RA; Stewart AO; Bouska JB; Harris RR; Hulkower KI; Malo PE; Bell RL; Carter GW; Brooks CD
J Med Chem; 2000 Aug; 43(17):3322-34. PubMed ID: 10966751
[TBL] [Abstract][Full Text] [Related]
29. Substituted indoles as potent and orally active 5-lipoxygenase activating protein (FLAP) inhibitors.
Frenette R; Hutchinson JH; Léger S; Thérien M; Brideau C; Chan CC; Charleson S; Ethier D; Guay J; Jones TR; McAuliffe M; Piechuta H; Riendeau D; Tagari P; Girard Y
Bioorg Med Chem Lett; 1999 Aug; 9(16):2391-6. PubMed ID: 10476875
[TBL] [Abstract][Full Text] [Related]
30. Pharmacodynamic and pharmacokinetic characterisation of RBx 7796: a novel 5-lipoxygenase inhibitor.
Shirumalla RK; Sharma P; Dastidar SG; Paliwal JK; Kakar S; Varshney B; Singh Saini G; Sattigeri V; Salman M; Ray A
Inflamm Res; 2008 Mar; 57(3):135-43. PubMed ID: 18369577
[TBL] [Abstract][Full Text] [Related]
31. Myocardial salvage induced by REV-5901: an inhibitor and antagonist of the leukotrienes.
Mullane K; Hatala MA; Kraemer R; Sessa W; Westlin W
J Cardiovasc Pharmacol; 1987 Oct; 10(4):398-406. PubMed ID: 2444792
[TBL] [Abstract][Full Text] [Related]
32. Lipoxygenase inhibitors, Part 6. Synthesis of new tetrahydropyrazine and other heterocyclic compounds by reaction of hydrazonoyl chlorides.
Frohberg P; Wiese M; Nuhn P
Arch Pharm (Weinheim); 1997 Mar; 330(3):47-52. PubMed ID: 9167446
[TBL] [Abstract][Full Text] [Related]
33. Effects of the arachidonate 5-lipoxygenase synthesis inhibitor A-64077 in intestinal ischemia-reperfusion injury.
Mangino MJ; Murphy MK; Anderson CB
J Pharmacol Exp Ther; 1994 Apr; 269(1):75-81. PubMed ID: 8169854
[TBL] [Abstract][Full Text] [Related]
34. Dioxabicyclooctanyl naphthalenenitriles as nonredox 5-lipoxygenase inhibitors: structure-activity relationship study directed toward the improvement of metabolic stability.
Delorme D; Ducharme Y; Brideau C; Chan CC; Chauret N; Desmarais S; Dubé D; Falgueyret JP; Fortin R; Guay J; Hamel P; Jones TR; Lépine C; Li C; McAuliffe M; McFarlane CS; Nicoll-Griffith DA; Riendeau D; Yergey JA; Girard Y
J Med Chem; 1996 Sep; 39(20):3951-70. PubMed ID: 8831761
[TBL] [Abstract][Full Text] [Related]
35. Transcellular synthesis of Cys-LT: from isolated cells to complex organ system.
Sala A; Rossoni G; Berti F; Müller-Peddinghaus R; Folco G
Adv Exp Med Biol; 1997; 433():95-8. PubMed ID: 9561112
[No Abstract] [Full Text] [Related]
36. Inhibition of leukotriene production by inhibitors of lipoxygenation.
Garland LG; Hodgson ST
Adv Prostaglandin Thromboxane Leukot Res; 1994; 22():33-48. PubMed ID: 7771347
[No Abstract] [Full Text] [Related]
37. N-omega-carbethoxypentyl-4-quinolones: a new class of leukotriene biosynthesis inhibitors.
Desideri N; Sestili I; Stein ML; Manarini S; Dell'Elba G; Cerletti C
Arch Pharm (Weinheim); 1997 Apr; 330(4):100-6. PubMed ID: 9230527
[TBL] [Abstract][Full Text] [Related]
38. Differential effects of arachidonoyl trifluoromethyl ketone on arachidonic acid release and lipid mediator biosynthesis by human neutrophils. Evidence for different arachidonate pools.
Fonteh AN
Eur J Biochem; 2002 Aug; 269(15):3760-70. PubMed ID: 12153573
[TBL] [Abstract][Full Text] [Related]
39. BIRM 270: a novel inhibitor of arachidonate release that blocks leukotriene B4 and platelet-activating factor biosynthesis in human neutrophils.
Farina PR; Graham AG; Hoffman AF; Watrous JM; Borgeat P; Nadeau M; Hansen G; Dinallo RM; Adams J; Miao CK
J Pharmacol Exp Ther; 1994 Dec; 271(3):1418-26. PubMed ID: 7996454
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of leukotriene biosynthesis.
Ford-Hutchinson AW
Ann N Y Acad Sci; 1991; 629():133-42. PubMed ID: 1952545
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
